Search research articles
Contact Us
Filters
Showing results (81-90 of 231) with videos related to
Page
of 24
Sort By:
Leukemia & Lymphoma
|
September 30, 2014
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States
Loretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.
American Journal of Hematology
|
July 19, 2017
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab
Mary-Kate Malecek, Adam M Petrich, Shaina Rozell, et al.
Leukemia & Lymphoma
|
December 23, 2014
Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource
Kitsada Wudhikarn, Brian J Smith, Anna M Button, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2013
Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma
Preethi Reddy Marri, Lucy S Hodge, Matthew J Maurer, et al.
American Journal of Hematology
|
October 19, 2011
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma
Carrie A Thompson, Matthew J Maurer, James R Cerhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
American Journal of Hematology
|
September 3, 2022
Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma
Juan Pablo Alderuccio, Isildinha M Reis, Thomas M Habermann, et al.
Hematological Oncology
|
June 5, 2018
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma
Carrie A Thompson, Kathleen J Yost, Matthew J Maurer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma
John P Leonard, Brian K Link, Christos Emmanouilides, et al.
Blood
|
July 11, 2006
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A Bowles, Siao-Yi Wang, Brian K Link, et al.
Page
of 24
Search research articles
Search
Showing results (81-90 of 231) with videos related to
Sort By:
Page
of 24
Leukemia & Lymphoma
|
September 30, 2014
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States
Loretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.
American Journal of Hematology
|
July 19, 2017
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab
Mary-Kate Malecek, Adam M Petrich, Shaina Rozell, et al.
Leukemia & Lymphoma
|
December 23, 2014
Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource
Kitsada Wudhikarn, Brian J Smith, Anna M Button, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2013
Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma
Preethi Reddy Marri, Lucy S Hodge, Matthew J Maurer, et al.
American Journal of Hematology
|
October 19, 2011
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma
Carrie A Thompson, Matthew J Maurer, James R Cerhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
American Journal of Hematology
|
September 3, 2022
Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma
Juan Pablo Alderuccio, Isildinha M Reis, Thomas M Habermann, et al.
Hematological Oncology
|
June 5, 2018
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma
Carrie A Thompson, Kathleen J Yost, Matthew J Maurer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma
John P Leonard, Brian K Link, Christos Emmanouilides, et al.
Blood
|
July 11, 2006
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A Bowles, Siao-Yi Wang, Brian K Link, et al.
Page
of 24